Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AL58805 + Eribulin |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AL58805 | AL 58805|AL-58805 | mTOR Inhibitor 52 PI3K Inhibitor (Pan) 44 | Limited information is currently available on AL58805, a putative dual-target PI3K/mTOR inhibitor (Sep 2026). | |
| Eribulin | Halaven | Antimicrotubule Agent 14 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07811232 | Phase Ib/II | AL58805 + AL8326 AL58805 + Eribulin AL58805 + Fulvestrant | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | Not yet recruiting | USA | 0 |